The total number of patients is high, but it's only 25 patients from the Rtx trial. From an open trial, that is.They're certainly looking in the right place and its a sizeable sample which is good.
Yes, you're right about repeated treatment, at least from my layman's perspective However, treatment of those with low antibodies is just as justified as it is for those with high antibodies - from the figure, around 50% of Rtx responders didn't have elevated β2 antibodies in the first place!This does not identify responders and nonresponders. What it does is show that patients with particular autoantibodies may respond. The fact that nonresponders did not show an antibody decline might however mean they are justified in repeated treatment until they do respond.
We don't really get any information about for whom Rtx might work out of this paper, do we? We get a hint on what Rtx might be doing for those who do have elevated antibodies, but we don't get any information on who might respond to Rtx based on the specific antibodies they tested?However, if it proves possible to select cases for rituximab based on data like this then that makes a huge difference to getting a therapeutic programme of the ground. One of the most important brakes on the programme is the worry that treatments like rituximab would have to be used hit and miss in a condition that is hard to pin down diagnostically and that may include people for whom this is the wrong approach. Take away that worry and treating ME by B cell targeting begins to look much more similar to lots of other diseases.
I'm not saying this piece of research isn't encouraging! I'm just thinking that some people might get discouraged when they read mature or less-mature conclusions about strong or not-so-strong correlations. Having read this thread before the paper, I caught myself thinking, damn, my IgG subclasses are quite low (IgG1 and IgG3), so probably I won't have elevated antiautobodies to β2 etc., which means I won't respond to Rtx - that's of course no valid conclusion, so there's hope Maybe I didn't read all the comments properly, but aren't we all a bit egoistic while we're on the hunt for a therapy that cures our very individual CFS? (apart from @Jonathan Edwards, who wants to help all of us at once ;-) )